Cancer therapy firm TriSalus Q3 revenue misses estimates

TriSalus Life Sciences

13/11/2025 21:15

Overview

TriSalus Q3 revenue grows 57% yr/yr but misses analyst expectations

Company reaffirms 2025 revenue growth guidance of at least 50%

Company lowers quarterly cash burn by approximately 50% quarter-over-quarter

Outlook

TriSalus reaffirms 2025 revenue growth guidance of at least 50%

Result Drivers

TRINAV ADOPTION - Increased sales of TriNav in liver-directed applications drove revenue growth

PEDD EXPANSION - Co is expanding PEDD technology to new embolization applications, contributing to growth

CASH BURN REDUCTION - Co reduced quarterly cash burn by 50% due to strategic shifts, including nelitolimod partnerships

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$11.57 mln
$11.76 mln (7 Analysts)
Q3 Gross Profit
$9.66 mln
Q3 Income from Operations
-$9.01 mln
Q3 Pretax Profit
-$10.81 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $11.00, about 59.8% above its November 12 closing price of $4.42

Press Release: ID:nBw88NYVba

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)